ReadoutThe short answer
A dental practice typically moves through six buying gates: a reason to evaluate, a defined current workflow, a mapped buying group, technical and site feasibility, commercial approval, and an adoption plan. Those gates are not a clean sales funnel. A clinician may like the system while a partner controls capital; a de novo may have funding but no final room plan; a DSO location may have local clinical interest but central procurement and IT approval.
The rep's job is to find the unresolved gate. Do not turn a visible service line into a claim of need, a positive demo into approval, or a signed order into successful adoption.
The six gates in a CBCT decision
| Gate | What the clinic is deciding | What the rep should establish | Common stall signal |
|---|---|---|---|
| 1. Reason to evaluate | What changed enough to make a CBCT conversation relevant now? | A named workflow problem, clinical sponsor, current alternative, and reason to investigate. | General technology interest with no specific problem or sponsor. |
| 2. Current workflow and day-one use | How are appropriately selected scans handled now, and which use cases must work at launch? | The present referral or imaging workflow, representative cases, day-one requirements, and explicit exclusions. | “We do implants” substitutes for a real workflow and selected-case baseline. |
| 3. Buying group and authority | Who recommends, uses, funds, approves, signs, accepts, and supports the system? | Separate owners for clinical approval, capital, IT, site work, contracting, and adoption. | An enthusiastic clinician is treated as the economic buyer. |
| 4. Technical and site feasibility | Can the intended configuration answer the required questions and work in this practice? | Task-based FOV and image requirements, software and data flow, room and delivery feasibility, local requirements, testing, storage, and support. | Site, IT, or regulatory work starts only after the final proposal. |
| 5. Commercial approval | Is the complete project acceptable compared with the status quo, referral, service, or upgrade alternatives? | Line-item lifecycle costs, finance path, warranty and service scope, objective demo criteria, references, and the formal approval artifact. | A headline price or verbal “yes” hides partner, lender, contract, or total-cost questions. |
| 6. Acceptance and adoption | Can the team release the system for use and sustain an appropriate workflow? | Site readiness, applicable acceptance testing, role-based training, protocol and interpretation ownership, QC, support escalation, and post-launch review. | Delivery or one training session is treated as project completion. |
Clinical justification stays separate from the ownership case. The FDA states that dental CBCT should be performed only when it is necessary to provide clinical information that other imaging modalities cannot provide. A seller can help a practice map workflows and requirements, but patient-specific imaging decisions remain with qualified clinicians.
Who is actually involved?
Owner-led practice
The owner-dentist may combine clinical, capital, and signature authority, but a partner, spouse, CPA, lender, manager, IT provider, installer, or physicist can still control a gate.
Multi-dentist group
A sponsor may need agreement from equity partners or specialty leads. Clarify whether the system serves one clinician, one department, one location, or a shared platform.
De novo or buildout
The lender, landlord, architect, contractor, equipment planner, IT provider, and opening schedule may shape the purchase before reliable case volume exists.
DSO-affiliated location
Local clinical judgment can coexist with central capital, procurement, IT, security, facilities, or approved-vendor processes. Ask what is local, regional, and central.
The ADA describes DSO arrangements as a continuum rather than one standard structure. That makes the buyer map an early discovery task, not a label a rep should infer from group affiliation. Review the ADA's guide to DSO business-services agreements.
What public research can—and cannot—tell a rep
| Public observation | Possible seller hypothesis | What must be verified |
|---|---|---|
| Implant, endodontic, surgical, orthodontic, or other 3D-associated services | A three-dimensional imaging workflow question may be relevant. | Which patient-specific questions lead to CBCT, how scans are handled today, and whether ownership is being considered. |
| New provider, service, location, expansion, or renovation | A clinical workflow or capital-planning window may exist. | Whether equipment scope remains open, who owns it, and what funding, site, or schedule gates apply. |
| A visible panoramic or CBCT system | An installed-base, service, software, integration, training, utilization, or configuration conversation may exist. | The exact system, configuration, support status, performance, utilization, and actual problem. |
| Digital planning, scanning, guided surgery, lab, or 3D-printing language | Data exchange and adjacent workflow may matter. | Which systems and modules are live, what files move between them, and where the handoff fails. |
| Multi-location or DSO affiliation | The buying path may include central standards or approvals. | The actual local, regional, and central decision rights for clinical, capital, IT, facilities, and contracting. |
None of these observations proves need, budget, authority, or intent. Use them to decide what to ask—not what to assert. For the full public-signal framework, see how to identify practices that may justify a CBCT conversation.
Twelve discovery questions that move the deal map forward
- What changed that made CBCT worth evaluating now?
- Which patient-specific clinical questions currently lead you to seek 3D imaging?
- How does an outside scan move from prescription through image receipt, review, documentation, and patient follow-up today?
- Which workflows must work on day one, and which are only future possibilities?
- Who owns clinical approval, capital approval, IT, site readiness, contract review, and signature authority?
- In this group, which decisions are local, regional, or central?
- What is the smallest and largest anatomical region required for each day-one use case?
- Which systems and files must work together—imaging, practice management, planning, scanning, lab, guide, or printing?
- Who has reviewed the room, delivery path, power, network, storage, shielding question, and applicable local requirements?
- What must the proposal include beyond the scanner: site work, software, workstations, testing, training, service, updates, and financing?
- What must the demo and reference calls prove, using whose cases and which intended users?
- What defines technical go-live and sustained adoption—and who owns each?
Why apparently good CBCT deals stall
The problem is too vague
The clinic is interested in technology, but no one can name the current workflow problem, day-one use, or reason to act now.
The sponsor is not the buyer
A clinician wants a demo, but a partner, lender, procurement team, or capital committee controls the real approval.
Site or IT arrives late
The proposal is built before anyone validates the room, delivery path, local requirements, workstations, storage, security, or actual interfaces.
The total project is hidden
Hardware price is clear, but licenses, modules, site work, testing, training, service, updates, labor, travel, and downtime are not.
The demo proves the wrong thing
Ideal vendor-selected images impress the room, but representative cases, real users, software modules, data flow, and support conditions remain untested.
Installation is treated as the finish
Acceptance, integration, role-specific training, interpretation, QC, and follow-up have no named owner.
AAPM recommends involving a dental-CBCT-experienced medical physicist before installation and describes acceptance testing and ongoing quality-control responsibilities. Review AAPM Task Group Report 261. Requirements also vary by state; the ADA's radiographic-imaging guidance lists areas that state rules may cover.
A practical rep qualification view
| Evaluation state | What it looks like | Recommended rep action |
|---|---|---|
| Well-formed evaluation | Named problem and sponsor; current workflow documented; day-one use cases defined; authority mapped; site and IT work started; commercial comparison and adoption owners visible. | Advance the specific unresolved gate. Keep the proposal tied to agreed requirements and evidence. |
| Relevant but unqualified | Product fit or timing is plausible, but current imaging, authority, site, funding, or adoption ownership is unknown. | Do not rush to a demo. Use discovery to turn unknowns into a real evaluation—or a clear reason to wait. |
| Wrong motion or wrong time | Referral works well; an existing system meets the need; the project is already awarded; capital sits elsewhere; or the team lacks a supported use case or adoption capacity. | Reroute to service, software, training, an adjacent workflow, monitoring, or no action. A credible “not now” improves the territory. |
Claims a credible rep should avoid
- “You do implants, so you need CBCT.” A service line is not a patient-specific clinical indication or ownership case.
- “CBCT is the standard of care.” Current guidance emphasizes selective, clinically justified use—not routine use across a broad category.
- “The system pays for itself after a fixed number of scans.” No universal threshold accounts for local workflow, appropriate use, financing, site cost, staffing, service, and alternatives.
- “It is DICOM compatible, so it will integrate.” The DICOM standard explains that conformance statements identify supported components; actual interoperability still needs knowledgeable comparison and validation. See the DICOM conformance standard.
- “Installation means the project is complete.” Acceptance, integration, training, interpretation planning, QC, and adoption still have to be owned.
Research basis and limits
This guide synthesizes current U.S. clinical, radiation-safety, quality-control, interoperability, security, practice-finance, and DSO guidance into a seller workflow. Strong evidence supports the gate categories; the exact order and role allocation vary by practice. No representative U.S. study was found that measures the prevalence, duration, or universal sequence of CBCT purchasing stages.
Primary references include the FDA dental CBCT overview, 2026 ADA/AAOMR patient-selection recommendations, AAPM Task Group Report 261, DICOM conformance guidance, and HHS security risk-analysis guidance. Clinical, regulatory, shielding, interpretation, financing, tax, and legal questions require current qualified review for the specific practice and jurisdiction.
Keep reading: choose the correct next motion with the CBCT opportunity-routing guide, identify the right accounts with the CBCT opportunity framework, or broaden the timing view with dental equipment buying signals.
Find the account. Then find the unresolved gate.
Readout helps dental equipment teams identify product-relevant accounts, review the public evidence, and give the rep a precise question to verify before the first conversation.